Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

ative risk reduction 46 percent; p<0.001)
  • Trend toward lower risk of major bleeding alone: 13 patients, 0.9 percent versus 25 patients,1.8 percent (relative risk reduction 48 percent; p=0.06)
  • A higher rate of acute coronary syndrome (ACS) events was observed in the dabigatran group versus warfarin (13 patients, 0.9 percent versus three patients, 0.2 percent, respectively; p=0.02)
  • RE-SONATE

    • Design: 1,343 patients randomized to dabigatran 150 mg (681 patients) or placebo (662 patients) for six months with extended follow-up to evaluate the long-term risk of recurrence (12 months after completion of study treatment)
    • Efficacy: 92 percent risk reduction for recurrent or fatal VTE with dabigatran versus placebo (three patients, 0.4 percent versus 37 patients, 5.6 percent; p<0.001 for superiority)
    • Safety: the incidence of major bleeding was two patients in the dabigatran group versus zero patients in the placebo group. A higher rate of major or clinically relevant bleeding in the dabigatran group versus no treatment was observed (36 patients, 5.3 percent versus 12 patients, 1.8 percent; p=0.001)

    * Pradaxa® (dabigatran etexilate mesylate) capsules are not approved by the U.S. Food and Drug Administration for the prevention of recurrent VTE or the treatment of acute VTE.

    About Pradaxa® (dabigatran etexilate mesylate) Capsules

    Indications and Usage
    Pradaxa® (dabigatran etexilate mesylate) capsules is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

    IMPORTANT SAFETY INFORMATION ABOUT PRADAXA

    CONTRAINDICATIONS
    PRADAXA is contraindicated in patients with:

    • Active pathological bleeding
    • A known serious hypersensitivity rea
      '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
    3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
    4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
    5. Shingles Vaccine is Safe, According to New Study
    6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
    7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
    11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... Market - Global Industry Analysis, Size, Share, Growth, ... to their offering. (Logo: ... are products which are used on patients in ... and in treatment of associated gingival tissues. This ...
    (Date:1/15/2014)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ... from institutional investors to purchase an aggregate of ... in an at-the-market registered direct offering, led by ... Company entered into definitive purchase agreements with these ... sell an aggregate of 3,603,603 shares of its ...
    (Date:1/15/2014)... January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ... with Teva Pharmaceutical Industries Ltd (NYSE: TEVA ...
    Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
    ... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that the first U.S. commercial implant of the ... Hines, Jr. VA Hospital in Chicago, IL. The procedure ... and Chief of Vascular Surgery & Endovascular Therapy at ...
    ... Britain,s best-loved comedienne and TV favourite Jo Brand has joined ... for a brand new comedy film (54 seconds) to launch ... film sees Jo Brand running around South London, in what ... her kitchen with Joanna Scanlan and produces a pint of ...
    Cached Medicine Technology:Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 3
    (Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
    (Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
    (Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
    (Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
    (Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
    Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
    ... Synthetech, Inc. (OTC,Bulletin Board: NZYM) today announced that ... become Synthetech,s President and Chief Executive Officer. Since,September ... and Chief,Operating Officer. Dr. Hahn will replace as ... continue as Synthetech,s Chairman of the Board.,Synthetech intends ...
    ... Industrial Control Repair, Inc.,(ICR), headquartered in Warren, Michigan, ... their superior delivery of MRO Asset Management and,industrial ... asset management solutions and selling refurbished,industrial equipment to ... honor at the annual Honda of America Manufacturing,MRO ...
    ... it will be several years before there,s widespread use ... new imaging device could one day help doctors detect ... and more accurately, researchers report. , If left undetected ... or acute glaucoma attack, which can result in permanent ...
    ... and Other Providers Would Likely Demand Similar,Treatment Next Year, ... (PCMA) released a new ad today warning policymakers,that other ... demand the "same prompt-pay deal" next year if Congress ... Medicare., "Paying one group of Medicare providers twice ...
    ... NEW YORK, June 9 Officials with the U.S.,Fund ... Inc.,announced the donation and delivery of 100,000 doses of ... to the,government of the former Soviet republic of Moldova, ... country., The vaccine is a combination vaccine against ...
    ... more sleepy, restless and stressed , , MONDAY, June 9 ... cell phones may be placing their health at risk ... Swedish study suggests. , The finding was presented Monday ... Baltimore. , "The message is that adolescents who use ...
    Cached Medicine News:Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 3Health News:Industrial Control Repair Named Honda of America Manufacturing's '2007 Supplier of the Year' 2Health News:New Imaging Tool Can Spot Glaucoma Risk 2Health News:New Imaging Tool Can Spot Glaucoma Risk 3Health News:New PCMA Ad: Pharmacist 'Prompt Pay' Will Trigger 'Domino Effect' Among Other Medicare Providers 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 3Health News:Too Much Cell Phone Time Takes Toll on Teen Sleep 2Health News:Too Much Cell Phone Time Takes Toll on Teen Sleep 3
    Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
    Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
    Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
    Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
    Medicine Products: